AbbVie Inc/ US00287Y1091 /
6/14/2024 10:10:00 PM | Chg. +2.03 | Volume | Bid2:00:00 AM | Ask2:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
168.59USD | +1.22% | 4.38 mill. Turnover: 439.66 mill. |
165.66Bid Size: 100 | 170.82Ask Size: 100 | 297.71 bill.USD | 3.55% | 61.75 |
GlobeNewswire
12:37 PM
CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...
GlobeNewswire
6/13
Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...
GlobeNewswire
6/13
CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...
GlobeNewswire
6/13
What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...
GlobeNewswire
6/12
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...
GlobeNewswire
6/12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
6/11
CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...
GlobeNewswire
6/8
CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...
GlobeNewswire
6/5
CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
6/4
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
6/3
ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...
GlobeNewswire
6/1
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...
GlobeNewswire
5/28
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...
GlobeNewswire
5/28
CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...
GlobeNewswire
5/28
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million